All In Biotech

NDA 021292 · Emd Serono INC

Euthyrox

Levothyroxine Sodium · Oral

OrphanDiscontinued

Last checked: Nov 20, 2026Latest source record: Apr 27, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2002

May 31, 2002

Approved uses

2

Original approval plus efficacy supplements

Registered trials

216

36 Phase 3, 17 recruiting

FAERS reports

0

0 serious, 0 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

No structured label for this application in openFDA. Older and discontinued products often have none.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Sep 14, 2018 Supplement 4 · Efficacy LabelLetter
  • May 31, 2002 Original approval · Type 5 - New Formulation or New Manufacturer OrphanLetterLabelReview
12 products under this application
  • EUTHYROX · LEVOTHYROXINE SODIUM 0.137MG · TABLET, ORAL · Discontinued · TE AB2
  • EUTHYROX · LEVOTHYROXINE SODIUM 0.112MG · TABLET, ORAL · Discontinued · TE AB2
  • EUTHYROX · LEVOTHYROXINE SODIUM 0.3MG · TABLET, ORAL · Discontinued
  • EUTHYROX · LEVOTHYROXINE SODIUM 0.088MG · TABLET, ORAL · Discontinued · TE AB2
  • EUTHYROX · LEVOTHYROXINE SODIUM 0.175MG · TABLET, ORAL · Discontinued · TE AB2
  • EUTHYROX · LEVOTHYROXINE SODIUM 0.05MG · TABLET, ORAL · Discontinued · TE AB2
  • EUTHYROX · LEVOTHYROXINE SODIUM 0.15MG · TABLET, ORAL · Discontinued · TE AB2
  • EUTHYROX · LEVOTHYROXINE SODIUM 0.125MG · TABLET, ORAL · Discontinued · TE AB2
  • EUTHYROX · LEVOTHYROXINE SODIUM 0.1MG · TABLET, ORAL · Discontinued · TE AB2
  • EUTHYROX · LEVOTHYROXINE SODIUM 0.2MG · TABLET, ORAL · Discontinued · TE AB2
  • EUTHYROX · LEVOTHYROXINE SODIUM 0.075MG · TABLET, ORAL · Discontinued · TE AB2
  • EUTHYROX · LEVOTHYROXINE SODIUM 0.025MG · TABLET, ORAL · Discontinued · TE AB2

Clinical trials

Interventional ClinicalTrials.gov studies with "Levothyroxine" as an intervention, any sponsor and status, largest first.

All 216 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals

No FAERS reports name this application.

FAERS reports by year

By the date FDA received the report.

No reports.

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Euthyrox (Levothyroxine Sodium)

2024 spending

$485K

Beneficiaries

22,247

69,130 claims

Per beneficiary

$22

$0.09 per unit

View as table
YearSpending
2020$9,198,928
2021$12,132,041
2022$10,513,004
2023$1,043,508
2024$484,551

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 614 on PubMed

Sponsor: Emd Serono INC

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.